Get the Stockscreener App
77.03
0.51%
-0.395
After Hours:
77.02
-0.005
-0.01%
Bright Minds Biosciences Inc stock is traded at $77.03, with a volume of 107.83K.
It is down -0.51% in the last 24 hours and up +7.98% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$77.42
Open:
$77.05
24h Volume:
107.83K
Relative Volume:
0.36
Market Cap:
$755.77M
Revenue:
-
Net Income/Loss:
$-19.80M
P/E Ratio:
-31.53
EPS:
-2.4426
Net Cash Flow:
$-14.56M
1W Performance:
-3.09%
1M Performance:
+7.98%
6M Performance:
-13.54%
1Y Performance:
+75.22%
1-Day Range:
$74.44
$78.91
1-Week Range:
$74.44
$87.00
52-Week Range:
$38.00
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
77.03 | 770.84M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences Stock Falls 4.60% as Investors Weigh BMB-101 Clinical Progress Against Biotech Development Risk - kalkine.ca
What is HC Wainwright's Forecast for DRUG FY2026 Earnings? - MarketBeat
Bright Minds Biosciences Slides as Biotech Volatility Returns — What Could Wake the Stock Up? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure — Can Clinical Momentum Offset Rising Correction Risk? - kalkine.ca
Psychedelic: Enveric, Helus, Bright Minds report earnings results - TipRanks
H.C. Wainwright reiterates Bright Minds stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Bright Minds stock rating at buy - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences Stock: An Epilepsy Story Keeps Drawing Biotech Money - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9%Should You Buy? - MarketBeat
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
TD Cowen Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating - Moomoo
Liquidity Mapping Around (DRUG) Price Events - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results - MarketBeat
Bright Minds (DRUG) reports Phase 2 seizure gains in treatment‑resistant epilepsy - Stock Titan
Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake - Stock Titan
Bright Minds Biosciences (DRUG) Slips to $78.00 as Traders Eye Support at $74.1Chart Pattern Alerts - Vinanet
Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going? - Kalkine Media
Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding - Stock Titan
Bright Minds Biosciences Inc. expected to post a loss of C$1.76 a shareEarnings Preview - TradingView
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet - finance.yahoo.com
Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase - kalkine.ca
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG) - Seeking Alpha
Bright Minds Biosciences (CN:DRUG): The Ticker Everyone's Talking About After a US$175M Raise and a Seizure Data Bombshell - kalkine.ca
Bright Minds Biosciences Inc (CN:DRUG) Jumps 4.05%: neuroscience biotech's Canadian line rose to C$114 on almost no volume, a thin-trading blip rather than - kalkine.ca
Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday - MarketBeat
Why (DRUG) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Bright Minds Biosciences (DRUG) Holds Gains Above $73 as Bulls Eye $77.47 ResistanceIV Crush Alert - Vinanet
Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG - MarketBeat
Janus Henderson Group PLC Raises Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
ADAR1 Capital Management LLC Has $2.47 Million Stock Position in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Inc (DRUG) Cash Flow - TradingKey
40,000 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Orbimed Advisors LLC - MarketBeat
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
DRUG|Bright Minds Biosciences Inc|Price:71.840|Chg%:+0.510 - TradingKey
Bright Minds Biosciences Inc (DRUG) Balance Sheet - TradingKey
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See a 27.16% Upside in Unity Software (U): Can the Stock Really Move This High? - Zacks Investment Research
Walleye Capital LLC Has $3.92 Million Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Zacks Research - MarketBeat
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences (DRUG) Rallies 4.25% as Shares Approach Key ResistanceVolatility Breakout Picks - vinanet.vn
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5%Should You Buy? - MarketBeat
Eli Lilly deal to buy AtaiBeckley (psychedelic) - KuCoin
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High? - Yahoo Finance
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):